CN115151250A - 用于治疗癌症或肿瘤的组合物和方法 - Google Patents

用于治疗癌症或肿瘤的组合物和方法 Download PDF

Info

Publication number
CN115151250A
CN115151250A CN202180016676.8A CN202180016676A CN115151250A CN 115151250 A CN115151250 A CN 115151250A CN 202180016676 A CN202180016676 A CN 202180016676A CN 115151250 A CN115151250 A CN 115151250A
Authority
CN
China
Prior art keywords
day
body weight
cancer
tumor
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202180016676.8A
Other languages
English (en)
Chinese (zh)
Inventor
姜信旭
金京洵
成智惠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obolato Co ltd
Original Assignee
Obolato Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obolato Co ltd filed Critical Obolato Co ltd
Publication of CN115151250A publication Critical patent/CN115151250A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180016676.8A 2020-02-24 2021-02-24 用于治疗癌症或肿瘤的组合物和方法 Withdrawn CN115151250A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062980645P 2020-02-24 2020-02-24
US62/980,645 2020-02-24
PCT/US2021/019457 WO2021173702A1 (en) 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor

Publications (1)

Publication Number Publication Date
CN115151250A true CN115151250A (zh) 2022-10-04

Family

ID=77490220

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180016676.8A Withdrawn CN115151250A (zh) 2020-02-24 2021-02-24 用于治疗癌症或肿瘤的组合物和方法

Country Status (8)

Country Link
US (1) US20230092005A1 (enExample)
EP (1) EP4110315A4 (enExample)
JP (1) JP2023514742A (enExample)
KR (1) KR20220145861A (enExample)
CN (1) CN115151250A (enExample)
AU (1) AU2021228654A1 (enExample)
CA (1) CA3168980A1 (enExample)
WO (1) WO2021173702A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102006775A (zh) * 2008-02-12 2011-04-06 托斯克公司 减少毒性的多柔比星助剂及其使用方法
US20170027891A1 (en) * 2008-09-02 2017-02-02 Oklahoma Medical Research Foundation Adjuvant chemotherapy for anaplastic gliomas
CN110392568A (zh) * 2017-01-19 2019-10-29 耳科制药公司 N-乙酰半胱氨酸的制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
WO2012106313A2 (en) * 2011-01-31 2012-08-09 Oklahoma Medical Research Foundation Ubiquitin interacting motif peptides as cancer therapeutics
KR101905864B1 (ko) * 2017-03-20 2018-10-08 아주대학교산학협력단 Sulf2 유전자를 이용한 소라페닙 치료에 대한 감수성 예측방법 및 sulf2 저해제를 포함하는 암 치료용 조성물
ES3063479T3 (en) * 2017-09-20 2026-04-16 Oklahoma Med Res Found Treatment of drug resistant gliomas
EP3787750A1 (en) * 2018-05-03 2021-03-10 Hough Ear Institute Methods for reducing accumulated pathologic tau protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102006775A (zh) * 2008-02-12 2011-04-06 托斯克公司 减少毒性的多柔比星助剂及其使用方法
US20170027891A1 (en) * 2008-09-02 2017-02-02 Oklahoma Medical Research Foundation Adjuvant chemotherapy for anaplastic gliomas
CN110392568A (zh) * 2017-01-19 2019-10-29 耳科制药公司 N-乙酰半胱氨酸的制剂及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吴睿等: "硫酸乙酰肝素与癌症的相关性及其在 癌症治疗中的应用策略", 《中国细胞生物学学报》, vol. 41, no. 8, pages 1665 *

Also Published As

Publication number Publication date
US20230092005A1 (en) 2023-03-23
KR20220145861A (ko) 2022-10-31
WO2021173702A1 (en) 2021-09-02
JP2023514742A (ja) 2023-04-07
EP4110315A1 (en) 2023-01-04
AU2021228654A1 (en) 2022-10-13
CA3168980A1 (en) 2021-09-02
EP4110315A4 (en) 2024-03-06
WO2021173702A8 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
JP6706369B2 (ja) 骨髄腫の治療
US20240350439A1 (en) Calcium lactate compositions and methods of use
CN112566660B (zh) 具有braf突变的癌症的组合疗法
RS66487B1 (sr) Inhibitor egfr za lečenje raka glave i vrata
BRPI0808635A2 (pt) Nanopartícula compreendendo rapamicina e albumina como agente anti-câncer
CN102427728A (zh) 用硫代秋水仙碱衍生物进行联合治疗
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN113398070A (zh) 利用氧气疗法的分割放疗和化疗
Wang et al. Nanoparticle co-delivery of carboplatin and PF543 restores platinum sensitivity in ovarian cancer models through inhibiting platinum-induced pro-survival pathway activation
KR20240158972A (ko) 소세포 폐암의 치료 방법
CN115151250A (zh) 用于治疗癌症或肿瘤的组合物和方法
TW202337897A (zh) 抗ｐｄ－１抗體和抗ｖｅｇｆ－ａ抗體的藥物組合及其使用方法
CN114099469A (zh) 一种复合纳米药物载体及其制备方法和应用
US11484591B2 (en) Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
TWI843217B (zh) 一種藥物組合及其應用
US20230058726A1 (en) Chemoprevention using controlled- release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
CN121041456A (zh) 一种聚乙二醇化伊立替康在治疗三阴性乳腺癌疾病中的应用
WO2024140833A1 (zh) 药物组合及其应用
CN110461311A (zh) 微细纳米化药剂及其应用
WO2025160930A1 (zh) 母帕司汀(Muparfostat)治疗胰腺癌的用途
WO2026037393A1 (zh) 一种抗体药物偶联物与酪氨酸激酶抑制剂的组合
WO2024231843A1 (en) Tretinoin liposome formulations and uses thereof to treat cancer
HK40118808A (zh) 全反式维甲酸脂质体及其应用於肿瘤治疗
WO2026046410A1 (zh) 一种抗体药物偶联物与免疫检查点抑制剂的组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20221004

WW01 Invention patent application withdrawn after publication